Cronos Group Inc.

NASDAQ:CRON

Drug Manufacturers - Specialty & Generic

Healthcare
$3.17 -0.56%

-$0.02 today

Market cap
$1.16B
Beta
1.25
P/E (TTM)
-488.3
EPS (TTM)
-$0.01
52W Low $1.84High $3.43

Volume 1.13M

Average 1.51M

CRON Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Cronos Group Inc.NASDAQ: CRON

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables dips below year-ago levels

Q1 FY2026 accounts payables of $1.19M (cash outflow) fell 27.3% year over year, behind the +125.3% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 0.8% of revenue in FY2025, down 5.6 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -27.3% toward the trailing-twelve-month pace of +125.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.19M-150.0% QoQ
Last fiscal yearDec 2025
$1.13M+115.1% YoY
LTMMar 2026
$1.6M+125.3% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.3%——
1 year+115.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
1.13M USD
Year-over-year change
+115.1%

Accounts Payables vs competitors

How CRON compares with its peers on the latest reported figures

  • CRON's LTM Mar 2026 accounts payables of $1.6M is the 10th largest of the 11 companies compared; the peer median is $3.27M.
  • Its year-over-year change of +125.3% is the 5th highest of 11, against a peer median of -53.3%.
  • Accounts payables amounts to 0.8% of revenue for CRON, versus a peer median of 2.2%.
CRON Competitors Peer median
Accounts Payables for CRON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$37.94M +15.0%+57.8%18.5%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$25.05M +537.3%—3.6%
EMBCEmbecta Corp.LTM Mar 2026$23.4M +2500.0%—2.2%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$12.56M -121.6%+83.7%1.7%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$11.03M -313.0%—1.4%
PCRXPacira BioSciences, Inc.LTM Mar 2026$9M -171.8%—1.2%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$6.22M +5837.6%——
XNCRXencor, Inc.LTM Jun 2026$6.13M -229.5%+0.3%5.8%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$4.34M +345.5%—21.7%
CRONCronos Group Inc.LTM Mar 2026$1.6M +125.3%—0.8%
IRMDIRadimed CorporationLTM Mar 2026$407.64K -186.3%—0.5%
Peer median (excluding CRON) $3.27M-53.3%+57.8%2.2%

Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(397.2M)(168.73M)(74.55M)40.02M(2.93M)
Depreciation & Amortization15.4M13.12M8.11M9.34M14.48M
Deferred Income Tax00000
Stock-Based Compensation10.15M15.12M8.77M8.7M7.05M
Change in Working Capital(4.84M)15.66M(26.47M)(311K)(35.02M)
Accounts Receivables(12.16M)(8.55M)(6.59M)(917K)(26.2M)
Inventory11.57M(7.22M)7.4M5.28M(10.58M)
Accounts Payables(1.6M)(863K)(773K)(7.45M)1.13M
Other Working Capital(2.65M)32.29M(26.51M)2.77M636.96K
Other Non-Cash Items222.88M35.89M41.31M(38.9M)42.73M
Operating Cash Flow(153.62M)(88.95M)(42.84M)18.84M26.32M
Capital Expenditures(12.26M)(5.03M)(3.42M)(13.15M)(26.17M)
Acquisitions (Net)0005.71M2.9M
Purchases of Investments(230M)(271.38M)(608.25M)(8.34M)(59.44M)
Sales of Investments215.3M268.87M532.84M181.9M5.15M
Other Investing Activities(3.06M)4.12M18.42M8.41M0
Investing Cash Flow(28.9M)(1.84M)(59.5M)175.15M(77.9M)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased0000(9.91M)
Dividends Paid00000
Other Financing Activities(13.44M)(2.9M)(1.03M)(1.23M)(10.34M)
Financing Cash Flow(13.44M)(2.9M)(1.03M)(1.23M)(20.25M)
Effect of Forex Changes4.91M(28.64M)8.01M(3.25M)3.89M
Net Change in Cash(191.05M)(122.33M)(95.35M)189.51M(67.94M)
Free Cash Flow(165.88M)(93.98M)(46.26M)5.69M151.61K

Cronos Group Inc.

NASDAQ:CRON

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.